Bufalin: Cardiotonics and Molecular Glue Degrader for Advanced Cancer Research

Executive Summary. Bufalin is a natural product cardiotonic steroid isolated from Chinese toad venom and is a validated apoptosis inducer in various cancer cell lines, including U-937 cells, through mitogen-activated protein kinase (MAPK) pathway activation (DOI:10.1002/advs.202506253). It acts as a molecular glue degrader of estrogen receptor alpha and directly targets serine/threonine kinase 33 (STK33), a pro-oncogenic protein in triple-negative breast cancer (TNBC) (DOI:10.1002/advs.202506253). Bufalin’s chemical properties include a molecular weight of 386.52, formula C24H34O4, and solubility in DMSO (≥38.7 mg/mL) and ethanol (≥8.44 mg/mL), with optimal storage at -20°C (APExBIO). The compound demonstrates approximately 98% purity by HPLC and NMR and is available for research-only use. This article expands on recent mechanistic advances, benchmarking studies, and critical workflow guidance, extending beyond prior Bufalin reviews such as Mechanistic Innovations in Cancer Research, by focusing on STK33 targeting and molecular glue mechanisms.

Biological Rationale

Bufalin is a cardiotonic steroid isolated from the venom of the Chinese toad (genus Bufo), traditionally used in Chinese medicine (APExBIO). Its core structure is a cyclopenta[a]phenanthrene backbone with hydroxyl and lactone functional groups. Bufalin exhibits multifaceted biological activities, including induction of apoptosis, cell differentiation, and perturbation of key signaling pathways in cancer cells. Notably, Bufalin interacts with serine/threonine kinase 33 (STK33), a protein highly expressed in TNBC and implicated in poor prognosis (DOI:10.1002/advs.202506253). The ability of Bufalin to degrade STK33 positions it as a promising agent for targeting oncogenic signaling in TNBC, where conventional therapeutic options are limited. In addition, Bufalin’s molecular glue activity toward estrogen receptor alpha broadens its utility in hormone receptor–negative and positive cancer models.

Mechanism of Action of Bufalin

Bufalin induces apoptosis in cancer cells via multiple, well-characterized mechanisms. In U-937 cells, Bufalin activates the AP-1 transcription factor through a MAPK-dependent pathway, leading to programmed cell death. In triple-negative breast cancer models, Bufalin binds to STK33, disrupting the STK33–HSP90 complex and promoting STK33 degradation. Methionine 245 of STK33 is critical for this interaction, as confirmed by site-directed mutagenesis and biotin-pulldown assays (DOI:10.1002/advs.202506253). Bufalin also acts as a molecular glue degrader for estrogen receptor alpha, facilitating receptor ubiquitination and proteasomal degradation. These actions collectively inhibit cell proliferation, migration, and tumorigenic signaling. Additional molecular targets include modulation of CPT1A, a key regulator of fatty acid oxidation in hepatocellular carcinoma, and broad MAPK/JNK/Wnt/β-catenin signaling regulation (APExBIO).

Evidence & Benchmarks

• Bufalin binds and degrades STK33 in TNBC models, leading to suppressed cell proliferation both in vitro and in vivo (Jiang et al., 2025, DOI:10.1002/advs.202506253).
• Bufalin-induced apoptosis in U-937 leukemia cells is mediated by AP-1 activation via the MAPK pathway (APExBIO).
• Bufalin targets CPT1A, contributing to metabolic disruption and growth inhibition in hepatocellular carcinoma (APExBIO).
• Bufalin demonstrates molecular glue degrader activity toward estrogen receptor alpha, resulting in receptor downregulation (Mechanistic Innovations in Cancer Research).
• Bufalin is supplied as a solid with a molecular weight of 386.52, C24H34O4, and ≥98% purity by HPLC and NMR (APExBIO).

This article extends previous work by providing updated, peer-reviewed evidence for STK33 targeting and workflow integration, expanding on the mechanistic focus of Bufalin: Cardiotonics and Molecular Glue in Triple-Negative Breast Cancer, which did not detail the STK33–Bufalin protein interaction specificity.

Applications, Limits & Misconceptions

Bufalin is primarily used in academic and translational research settings as a tool compound to interrogate apoptosis, molecular glue degradation, and protein–protein interaction networks in cancer biology. Its validated targets in TNBC and hepatocellular carcinoma make it suitable for mechanistic, cell-based, and in vivo studies. The compound’s high purity and well-characterized solubility profile support reproducible assay development. However, Bufalin is strictly intended for research use only and is not approved for diagnostic or therapeutic use in humans.

Common Pitfalls or Misconceptions

• Bufalin is not water-soluble; improper vehicle selection can lead to precipitation and loss of activity.
• Bufalin is not a clinically approved drug and should not be used in therapeutic applications or human studies.
• Not all cancer cell lines respond equally; efficacy is best established in TNBC, hepatocellular carcinoma, and select leukemia models.
• Storage above -20°C can compromise compound stability and purity.
• Misidentifying target specificity; while Bufalin degrades STK33 and ERα, off-target effects are possible and require control validation.

This clarification addresses over-generalizations found in sources like Bufalin: Molecular Glue Degrader and Apoptosis Inducer in Cancer, which did not emphasize vehicle or cell-line context.

Workflow Integration & Parameters

Bufalin (SKU N1507) from APExBIO is provided as a solid and should be dissolved in DMSO (≥38.7 mg/mL) or ethanol (≥8.44 mg/mL) for experimental use. Solutions should be prepared under sterile conditions and stored at -20°C for optimal stability. For in vitro cancer studies, typical working concentrations range from 10 nM to 1 μM, depending on cell type and assay duration. For in vivo xenograft models, dosing regimens should be based on published pharmacokinetic and toxicity data. Controls should include vehicle-only and, where possible, STK33 or ERα knockdown to confirm specificity. Purity (≥98%) is validated by HPLC and NMR, ensuring batch-to-batch reproducibility.

For protocol benchmarking and troubleshooting, see the detailed workflows in Bufalin (SKU N1507): Evidence-Based Workflows for TNBC and HCC, which this article updates by incorporating new STK33 mechanistic data and solubility best practices.

Conclusion & Outlook

Bufalin is a unique research tool at the intersection of natural product pharmacology and targeted cancer therapy. Its dual role as a cardiotonic steroid and molecular glue degrader positions it as a next-generation compound for dissecting apoptotic and oncogenic signaling. Peer-reviewed evidence establishes Bufalin’s efficacy in degrading STK33 and ERα in TNBC and hepatocellular carcinoma models. APExBIO supplies high-purity Bufalin (SKU N1507) for research use, supporting reproducible, mechanistically driven oncology studies. Ongoing research will clarify additional targets, safety profiles, and translational opportunities. For further reading, see Bufalin: Mechanistic Clarity and Strategic Guidance for TNBC and HCC, which this article extends by providing updated STK33 targeting evidence and practical workflow advice.